- Home
- CLRB vs DPRO Comparison
CLRB vs DPRO Comparison
Compare CLRB & DPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLRB
- DPRO
- Stock Information
- Founded
- CLRB 2002
- DPRO 1998
- Country
- CLRB United States
- DPRO Canada
- Employees
- CLRB N/A
- DPRO N/A
- Industry
- CLRB Biotechnology: Pharmaceutical Preparations
- DPRO Aerospace
- Sector
- CLRB Health Care
- DPRO Industrials
- Exchange
- CLRB Nasdaq
- DPRO Nasdaq
- Market Cap
- CLRB 10.7M
- DPRO 9.3M
- IPO Year
- CLRB N/A
- DPRO N/A
- Fundamental
- Price
- CLRB $0.25
- DPRO $4.68
- Analyst Decision
- CLRB Buy
- DPRO Strong Buy
- Analyst Count
- CLRB 2
- DPRO 2
- Target Price
- CLRB $28.00
- DPRO $6.00
- AVG Volume (30 Days)
- CLRB 3.8M
- DPRO 732.7K
- Earning Date
- CLRB 11-18-2024
- DPRO 11-14-2024
- Dividend Yield
- CLRB N/A
- DPRO N/A
- EPS Growth
- CLRB N/A
- DPRO N/A
- EPS
- CLRB N/A
- DPRO N/A
- Revenue
- CLRB N/A
- DPRO $4,340,793.00
- Revenue This Year
- CLRB N/A
- DPRO $30.90
- Revenue Next Year
- CLRB N/A
- DPRO $112.38
- P/E Ratio
- CLRB N/A
- DPRO N/A
- Revenue Growth
- CLRB N/A
- DPRO N/A
- 52 Week Low
- CLRB $0.23
- DPRO $1.55
- 52 Week High
- CLRB $4.45
- DPRO $13.00
- Technical
- Relative Strength Index (RSI)
- CLRB 6.45
- DPRO 61.88
- Support Level
- CLRB $0.23
- DPRO $4.14
- Resistance Level
- CLRB $0.28
- DPRO $5.34
- Average True Range (ATR)
- CLRB 0.07
- DPRO 0.81
- MACD
- CLRB -0.10
- DPRO 0.08
- Stochastic Oscillator
- CLRB 2.70
- DPRO 69.43
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. Its PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
About DPRO Draganfly Inc.
Draganfly Inc is a Canada based company. It is engaged in the provision of engineering services and the manufacture of commercial unmanned vehicle systems and software. The company operates in Canada, the United States, and Internationally. The three segments are Drones, Vital (Vital Intelligence), and Corporate. The Drones segment derives its revenue from products and services related to the sale of unmanned aerial vehicles (UAV). The Vital segment derives its revenue from the sale of products that measure vitals to help detect symptoms from large groups of people from a distance. The Corporate segment includes all costs not directly associated with the Drone and Vital segments. It generates majority of its revenue from Drones segment.